More on TRUFF

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:TRUFF)
Delayed: 0.02 --0 (-0%)
Prev. Close $0.02  
Open$0.02 
52 Wk High$ 
52 Wk Low$ 
Day High$0.02 
Day Low$0.02 
P/E N/A  
EPS$ 
Volume1,881 

Friends, Peers and Foes (?): MDXXF (more...)

Oct 28, 2026 08:03 AM Rhelion unit to supply psilocybin drug to Sweden university trial
Oct 28, 2026 08:03 AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder
Oct 16, 2026 08:56 AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depressio
Oct 14, 2026 08:35 AM Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
Oct 8, 2026 08:20 AM Rhelion unit to supply psilocybin for UCSF HIV-meth study
Oct 8, 2026 08:20 AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorde
Sep 29, 2026 07:54 AM Rhelion unit ships psilocybin drug to University of Calgary PTSD trial
Sep 29, 2026 07:54 AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Viol
Sep 25, 2026 08:49 AM Rhelion unit expands psilocybin supply deal for Italian clinical trial
Sep 25, 2026 08:49 AM Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resista
View All Articles

Entities mentioned with TRUFF

View All Entities